Ratings by Evercore ISI (Umer Raffat)

Date CompanySymbol Type Rating
(Past)
PT
(Past)
Start $
(End $)
% Chg. Details
5/14/2026 Biogen BIIB New Coverage Outperform
(N/A)
204.53
(197.19)
-3.59% Details
5/12/2026 Kailera Therapeutics KLRA New Coverage Outperform
(N/A)
22.93
(21.37)
-6.8% Details
1/6/2026 Vaxcyte PCVX Maintain Outperform
(N/A)
 
 
  Details
5/2/2025 Organon & Co. OGN Downgrade In Line
(Outperform)
12.93
(13.45)
4.02% Details
2/25/2025 Metsera Inc MTSR New Coverage Outperform
(N/A)
29.81
(70.50)
136.5% Details
7/16/2024 Spyre SYRE New Coverage Outperform
(N/A)
28.80
(97.05)
236.98% Details
6/14/2024 Gilead Sciences GILD Maintain Outperform
(N/A)
 
 
  Details
3/8/2024 Amylyx Pharmaceuticals inc. AMLX Downgrade In Line
(Outperform)
18.97
(16.37)
-13.71% Details
2/28/2024 Fractyl Health Inc GUTS New Coverage Outperform
(N/A)
9.12
(0.83)
-90.9% Details
2/16/2024 Rapt Therapeutics RAPT New Coverage Outperform
(N/A)
25.54
(58.02)
127.17% Details
10/24/2023 Alkermes ALKS Upgrade Outperform
(In Line)
24.43
(48.07)
96.77% Details
7/17/2023 Apellis Pharmaceuticals APLS Maintain Outperform
(N/A)
 
 
  Details
6/21/2023 Centessa Pharmaceuticals CNTA New Coverage Outperform
(N/A)
5.50
(40.50)
636.36% Details
5/30/2023 Pfizer PFE Maintain Outperform
(N/A)
 
 
  Details
5/18/2023 Teva Pharma TEVA Upgrade Outperform
(In Line)
8.13
(33.21)
308.49% Details
5/11/2023 Phathom Pharmaceuticals PHAT Upgrade Outperform
(In Line)
12.43
(10.86)
-12.63% Details
3/7/2023 Mineralys Therapeutics, Inc. MLYS New Coverage Outperform
(N/A)
18.96
(25.61)
35.07% Details
2/9/2023 Amylyx Pharmaceuticals inc. AMLX Maintain Outperform
(N/A)
 
 
  Details
1/20/2023 Gilead Sciences GILD Maintain Outperform
(N/A)
 
 
  Details
11/2/2022 Legend Biotech Corp. LEGN New Coverage Outperform
(N/A)
49.82
(29.30)
-41.19% Details
9/13/2022 Cerevel Therapeutics CERE New Coverage Outperform
(N/A)
31.08
(44.96)
44.66% Details
5/6/2022 Phathom Pharmaceuticals PHAT Downgrade In Line
(Outperform)
13.07
(10.86)
-16.91% Details
2/2/2022 Amylyx Pharmaceuticals inc. AMLX New Coverage Outperform
(N/A)
23.18
(18.97)
-18.16% Details
6/10/2021 Organon & Co. OGN New Coverage Outperform
(N/A)
28.45
(13.45)
-52.72% Details
3/12/2021 Kodiak Sciences Inc. KOD New Coverage Outperform
(N/A)
126.89
(37.05)
-70.8% Details
12/8/2020 Mirati Therapeutics MRTX New Coverage Outperform
(N/A)
233.26
(58.70)
-74.83% Details
11/25/2020 Atea Pharmaceuticals AVIR New Coverage Outperform
(N/A)
34.07
(4.48)
-86.85% Details
11/23/2020 Arcus Biosciences RCUS New Coverage Outperform
(N/A)
24.38
(28.18)
15.59% Details
7/14/2020 Royalty Pharma RPRX New Coverage In Line
(N/A)
47.64
(55.35)
16.18% Details
1/21/2020 Amgen AMGN Upgrade Outperform
(In Line)
241.49
(347.01)
43.7% Details
11/20/2019 Phathom Pharmaceuticals PHAT New Coverage Outperform
(N/A)
24.27
(10.86)
-55.25% Details
8/7/2019 Teva Pharma TEVA Downgrade In Line
(Outperform)
7.06
(33.21)
370.4% Details
7/2/2019 Dova Pharmaceuticals Inc DOVA Upgrade Outperform
(In Line)
14.10
(28.04)
98.87% Details
1/28/2019 Amgen AMGN Downgrade In Line
(Outperform)
200.97
(241.49)
20.16% Details
11/16/2018 Molecular Templates MTEM New Coverage Outperform
(N/A)
4.40
(0.11)
-97.5% Details
8/24/2018 Mylan MYL Upgrade Outperform
(In Line)
37.86
(15.86)
-58.11% Details
8/13/2018 Teva Pharma TEVA Maintain Outperform
(N/A)
 
 
  Details